At a glance
- Compounded semaglutide as an essential copy became unlawful on May 22, 2025 after the FDA closed the shortage window; anyone still selling it that way is operating in a legally contested space.
- NovoCare Pharmacy self-pay Wegovy runs $199 for the first two 0.25 or 0.5 mg fills through Dec 31, 2026, then $349 a month for every standard dose.
- Oral Wegovy 1.5 mg and 4 mg self-pay through NovoCare is $149 a month, the cheapest legitimate FDA-approved semaglutide entry point in the US.
- Compounded semaglutide through telehealth partners like Bodybuilding Health+ starts at $139 a month on 12-month plans, contingent on documented clinical need per 503A rules.
- STEP 1 showed 14.9% mean weight loss at 68 weeks on the 2.4 mg dose (Wilding et al., NEJM 2021, PMID 33567185); STEP 1 extension showed patients regained 11.6 percentage points of that loss within a year of stopping.
The cheapest semaglutide without insurance in 2026 is not the compounded vial that dominated 2024. That door closed on May 22, 2025. What replaced it is a stack of five real lanes, priced between $139 and $349 a month, and the right pick depends on whether you want a legally settled FDA-approved product or a personalized 503A formulation your prescriber will need to justify in writing.
This is a working price map. It ranks every legitimate US path from cheapest to most expensive, names the vendors and the numbers, and closes with what the trial data says the money actually buys.
What "cheapest semaglutide" now means in 2026
The word "cheapest" got redefined in 2025. For most of 2024 it meant a $199 monthly membership at a telehealth clinic that shipped compounded semaglutide from a 503A pharmacy operating under an FDA shortage exemption. That exemption ended.
The FDA declared the semaglutide shortage resolved on February 21, 2025. 503A compounding pharmacies had a wind-down deadline of April 22, 2025, and 503B outsourcing facilities had until May 22, 2025 (Alston & Bird 2025 client advisory). Compounding an "essentially a copy" version of Ozempic or Wegovy is no longer a lawful mass-market activity, regardless of what a website tells you. A 503A pharmacy can still compound a personalized formulation for a specific patient with a documented clinical need, but that is a narrow clinical exception, not a cheap-brand substitute.
That regulatory reset reordered the price ladder. Novo Nordisk answered by launching NovoCare Pharmacy, a cash-pay direct-to-patient channel with $199 introductory and $349 ongoing pricing on brand Wegovy pens. Six months later, the FDA approved oral semaglutide 25 mg for weight management on the strength of OASIS 4, and NovoCare listed the pill at $149 a month for the 1.5 mg and 4 mg doses through August 31, 2026 (Wharton et al., NEJM 2025, PMID 40934115). The compounded lane still exists, but the honest brand path is now competitive on price for the first time.
Our semaglutide guide covers the pharmacology; this piece is purely about what to pay and where.
The five real lanes, ranked by monthly cost
Prices below are the drug-plus-program cost for a full month at a maintenance dose in the continental US as of August 2026. All numbers are verified from vendor pages linked inline. Insurance is out of scope; if you have Wegovy or Ozempic coverage, run that lane first and stop reading.
| Lane | Monthly cost | What you get | Legally settled |
|---|---|---|---|
| Oral Wegovy 1.5 mg or 4 mg via NovoCare | $149 | FDA-approved pill, 30 tablets, direct ship | Yes |
| Compounded semaglutide via 12-mo telehealth plan | $139 to $199 | Multi-dose vial, program membership, US-licensed clinician | Personalized-need 503A only |
| Injectable Wegovy 0.25 or 0.5 mg via NovoCare (intro) | $199 for 2 fills | FDA-approved 4-pen box, direct ship | Yes |
| Ozempic cash pay at Costco with member intro | $199 first 2 months, $349 after | FDA-approved 4-week pen | Yes |
| Injectable Wegovy any dose via NovoCare (ongoing) | $349 | FDA-approved 4-pen box | Yes |
The two cheapest rows deserve their own sections because they are the ones a searcher can plausibly be talked into (or out of) by bad information.
Lane 1: Oral Wegovy 1.5 mg or 4 mg via NovoCare, $149 a month
Novo Nordisk's oral Wegovy is the same molecule as the injectable, delivered as 30 tablets a month. NovoCare self-pay pricing lists 1.5 mg and 4 mg at $149 a month, with the 4 mg promotional price locked through August 31, 2026 (rising to $199 after that). One "month" is one bottle of 30 tablets, shipped free (Novo Nordisk Wegovy price guide, PDF).
The Phase 3 OASIS 4 trial that got the pill approved randomized 307 adults with obesity or overweight to oral semaglutide 25 mg or placebo for 64 weeks. Full-adherence weight loss reached 16.6% versus 2.7% on placebo (Wharton, Aroda et al., NEJM 2025, PMID 40934115). That is within striking distance of the injectable 2.4 mg 14.9% figure from STEP 1, on a lower-effort dosing form.
Two catches to think about before buying pill-first. First, the $149 tier is the 1.5 mg or 4 mg dose. The 25 mg full-effect dose used in the OASIS 4 trial is not in the $149 pricing tier. Second, oral semaglutide requires a 30-minute fasting window with a small sip of water, taken first thing on an empty stomach. Miss the window and absorption drops sharply.
For readers weighing pill versus injection at that specific budget, our oral semaglutide vs orforglipron guide covers the full oral GLP-1 field at every dose and pipeline stage.
Lane 2: Compounded semaglutide via 503A telehealth, $139 to $199 a month
This is the lane that changed the most in 2025. Post-May 22, 2025, a 503A pharmacy can still compound semaglutide for a specific patient whose clinician documents a personalized medical need (usually an inability to tolerate a commercial formulation, an allergy to an inactive ingredient, or a non-standard dose). It cannot mass-market copies of Wegovy under the old shortage-exemption umbrella. Our 503A peptide compounding review covers the enforcement picture in more detail.
The vetted telehealth partners we track today price it this way:
- Bodybuilding Health+ lists compounded semaglutide from $139 a month on the 12-month plan, $179 month-to-month. LegitScript-verified, US-licensed clinicians and pharmacies. Full breakdown in our Bodybuilding Health+ review.
- Yucca Health lists Semaglutide+ from $206 a month on the 6-month plan, focused on the personalized-formulation angle. Our Yucca Health review walks the intake and shipping.
- LIV BODY Medical starts at $179 a month for compounded semaglutide, positioned as a women-focused wellness program.
Everything on this row is contingent on the prescriber writing a personalized-need justification the pharmacy can defend. If a site is offering compounded semaglutide with no intake beyond a checkbox, that is not a compliant program; it is a legally exposed one. The FDA's own compounder-policy statement is the primary source on what compliant now means.
Our full price ladder across the compounded telehealth partners lives at compounded semaglutide online, and the head-to-head against tirzepatide compounders is at cheapest GLP-1 options.
Lane 3: NovoCare Pharmacy self-pay Wegovy pens, $199 intro or $349 ongoing
NovoCare Pharmacy is Novo Nordisk's direct cash-pay channel. New patients pay $199 for each of the first two monthly fills at 0.25 mg or 0.5 mg through December 31, 2026, then $349 a month for every standard dose from 0.25 mg through 2.4 mg. The 7.2 mg Wegovy HD (the STEP UP trial dose) is $399 a month. Shipping is free; NovoCare does not accept insurance (NovoCare Wegovy pharmacy page).
Two features distinguish this row from any pharmacy counter. The vials in the box are Lilly-authenticated originals; there is no gray-market purity question. And the shipment does not depend on a compounder or a shortage: as long as Novo makes the pen, NovoCare ships it. The trade-off is that $349 a month is roughly 2.5x the compounded telehealth floor, and the drug is billed in a $349 box regardless of which titration step you sit on.
For readers who want the dosing schedule side by side with what the pen supports, our Wegovy dosage chart breaks out the four-week titration through 2.4 mg, and the semaglutide dosage chart tracks the same schedule for compounded multi-dose vials.
Lane 4: Ozempic cash pay at Costco or NovoCare
Ozempic is semaglutide too, dosed for type 2 diabetes rather than weight loss. If your prescriber writes it off-label for weight management, the cheapest cash-pay path is:
- Costco Pharmacy self-pay, $349 a month for active members, $199 introductory for the first two months.
- NovoCare Pharmacy self-pay, $349 to $499 a month depending on dose.
- GoodRx coupons through participating pharmacies. GoodRx pricing on Ozempic without any manufacturer offer runs $800 to $880 a month; the $149 GoodRx headline number is a Novo-offer coupon that requires eligibility (GoodRx Ozempic page).
Ozempic and Wegovy are the same molecule at different maintenance doses. That is why our Ozempic vs Wegovy piece treats the question as a dosing problem, not a drug problem.
Lane 5: Retail pharmacy sticker price
If none of the above lanes work in your state or plan, brand Ozempic runs $998 to $1,212 a month at retail, and brand Wegovy runs $1,349 a month. These numbers exist mostly so cheaper lanes look reasonable. Nobody with the option to route through NovoCare or a vetted compounder should pay a retail sticker.
The all-in monthly cost, side by side
Not every "monthly" number in the sections above bundles the same things. This is the total out-of-pocket you write on your budget, membership plus drug plus shipping, at each maintenance dose:
| Path | Drug | Membership | Shipping | Total |
|---|---|---|---|---|
| Oral Wegovy 1.5 mg, NovoCare | $149 | $0 | $0 | $149 |
| Compounded semaglutide, Bodybuilding Health+ 12-mo | Included | Included | Included | $139 |
| Compounded semaglutide, LIV BODY 12-mo | Included | Included | Included | $179 |
| Injectable Wegovy 0.5 mg intro, NovoCare | $199 | $0 | $0 | $199 |
| Compounded semaglutide, Yucca 6-mo | Included | Included | Included | $206 |
| Injectable Wegovy any standard dose, NovoCare | $349 | $0 | $0 | $349 |
| Injectable Wegovy 7.2 mg HD, NovoCare | $399 | $0 | $0 | $399 |
The compounded telehealth floor beats the cheapest brand-injectable path by roughly $210 a month, and the pill beats the compounded floor at the two lowest doses. A patient who tolerates the pill's fasting window and needs 1.5 mg or 4 mg is looking at the honestly cheapest legitimate semaglutide in America right now.
What the drug actually does at these prices
Cheap only matters if the drug works. Semaglutide is unusually well characterized because Novo ran the STEP program.
- STEP 1 (2021): 1,961 adults with obesity or overweight, 68 weeks, once-weekly 2.4 mg subcutaneous. Mean weight loss 14.9% versus 2.4% on placebo. 86% of the semaglutide group hit at least 5% loss (Wilding et al., NEJM 2021, PMID 33567185).
- STEP 5 (2022): 304 adults, 104 weeks. Mean loss 15.2% versus 2.6% on placebo, with 77.1% of the semaglutide arm reaching at least 5% (Garvey et al., Nature Medicine 2022, PMID 36216945). This is the two-year answer to "does it plateau."
- SELECT (2023): 17,604 adults with established cardiovascular disease and BMI 27 or higher, no diabetes. Semaglutide 2.4 mg produced a 20% reduction in the composite of cardiovascular death, nonfatal MI, and nonfatal stroke (Lincoff et al., NEJM 2023, PMID 37952131).
- OASIS 4 (2025): 307 adults, 64 weeks, oral semaglutide 25 mg. Full-adherence weight loss 16.6% versus 2.7% on placebo (Wharton et al., NEJM 2025, PMID 40934115). The trial that made the pill lane real.
Bottom line: At the compounded telehealth floor, you are paying roughly $139 a month for a drug with 14.9% mean weight loss and a 20% MACE reduction in the SELECT population. At retail sticker, you are paying $1,349 for the same drug.
Weight regain when you stop
The catch every cash-pay buyer should price into the decision is what happens after discontinuation. The STEP 1 extension followed 327 participants after week 68. From week 68 to week 120, the semaglutide arm regained 11.6 percentage points of the lost weight, while the placebo arm regained 1.9 percentage points, leaving net losses of 5.6% and 0.1% respectively at week 120 (Wilding et al., Diabetes Obes Metab 2022, PMID 35441470). Cardiometabolic gains reverted toward baseline in the same window.
Semaglutide is a chronic-treatment drug, not a 12-week course. If the honest budget is 12 to 24 months, the compounded telehealth lane and the pill lane are meaningfully cheaper over time than any brand-injectable lane. If it is 12 weeks, none of these lanes is a good use of the money; a diet-only trial with periodic lab tests is a better spend.
Red flags on the "cheapest" side of the ladder
Not every low price is a real one. Three tells worth naming:
- "Compounded Wegovy" for $79 a month with no intake beyond a card capture. Post-May 2025, no lawful 503A program prices semaglutide this way. That is either counterfeit product or a legally exposed vendor about to be shut down.
- Research-chemical semaglutide vials sold on peptide sites. These are not for human use, purity is not certified, and one JMIR-style analysis of gray-market GLP-1s reported active ingredient content ranging from 7.7% to 144% of label. Use of the phrase "for research purposes only" on a weight-loss messaging site is a warning, not a disclaimer.
- Overseas shipping with no US pharmacy license. Legitimate semaglutide distribution in the US goes through licensed pharmacies. A Mexican or Indian dropshipper offering brand pens at half NovoCare pricing is not part of the legitimate supply chain.
Our gray-market sourcing truth audit walks through the actual purity data on unregulated GLP-1 vials.
Which lane fits which person
Tip: If your goal is the lowest monthly bill on FDA-approved semaglutide and you can hold a 30-minute fasting window each morning, oral Wegovy 1.5 mg through NovoCare at $149 a month is the answer for most people. If you need the injectable and want the compounded price, Bodybuilding Health+ on a 12-month plan at $139 a month clears the price bar with a US-licensed clinician on the intake.
The decision tree in short:
- Cheapest legitimate brand: Oral Wegovy 1.5 mg or 4 mg via NovoCare, $149.
- Cheapest injectable, brand: NovoCare intro pens for the first two fills at $199, then $349.
- Cheapest injectable, compounded: Bodybuilding Health+ 12-month plan at $139, contingent on the personalized-need justification the pharmacy can defend.
- If the compounded telehealth floor doesn't apply in your state: Yucca Health at $206 a month or LIV BODY at $179 are the fallback partners we vet.
- If you're comparing to the other big GLP-1: Our tirzepatide vs semaglutide 2026 piece runs both molecules head to head.
For the full cross-molecule cost map that includes the tirzepatide side, our cheapest GLP-1 options page keeps the vendor pricing current across both drugs.
What is coming next, and what to expect on generic price
Semaglutide's US composition-of-matter patent runs into 2032, with some formulation patents extending further. Do not expect a true generic before 2031 to 2033. Our generic semaglutide patent expiry timeline tracks the patent-cliff dates and the Canadian and Indian launch schedules that lead the US market by roughly a year.
Until then, "cheapest semaglutide without insurance" means one of the five lanes above. The May 2025 compounding reset already ran; the pill launch already ran; NovoCare's cash-pay ladder is set through the end of 2026. The next real price move is either a NovoCare tier extension or a compliant compounded program surviving an FDA inspection with a novel personalized-need protocol. Neither has happened yet.
The disclaimer
This article is for research and educational purposes only. It is not medical advice, a prescription, or an endorsement of any specific telehealth platform or pharmacy. Semaglutide is a prescription-only drug in the United States; obtaining it without a prescription is illegal and unsafe. Any decision about starting, switching, or stopping a GLP-1 receptor agonist should involve a licensed clinician who has reviewed your personal and family history, including any history of medullary thyroid cancer, MEN 2, pancreatitis, or diabetic retinopathy. Prices, plan tiers, and telehealth availability change frequently; confirm current pricing directly with the vendor before acting.
